Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naldemedine - Shionogi

Drug Profile

Naldemedine - Shionogi

Alternative Names: Rizmoic; S-297995; Symproic

Latest Information Update: 24 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer Purdue Pharma; Shionogi
  • Class Antiemetics; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Constipation

Most Recent Events

  • 19 Jun 2019 Shionogi and Ferrer enters a marketing agreement for naldemedine for opioid-induced constipation in Spain
  • 22 May 2019 Naldemedine licensed to Molteni Therapeutics in Italy and Poland
  • 17 Apr 2019 Shionogi plans to initiate a clinical study of Naldemedine in paediatric patients with opioid-induced constipation in EU, in accordance with paediatric investigation plan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top